

# Juan Fortea

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3037161/publications.pdf>

Version: 2024-02-01

235  
papers

12,218  
citations

34076

52  
h-index

36008

97  
g-index

256  
all docs

256  
docs citations

256  
times ranked

13864  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
2	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
3	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
4	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	5.8	600
5	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
6	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	3.3	392
7	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimer's and Dementia, 2019, 15, 292-312.	0.4	310
8	Behavioural and psychological symptoms of dementia in Down syndrome: Early indicators of clinical Alzheimer's disease?. Cortex, 2015, 73, 36-61.	1.1	201
9	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
10	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	6.3	164
11	Cerebrospinal Fluid Clearance in Alzheimer Disease Measured with Dynamic PET. Journal of Nuclear Medicine, 2017, 58, 1471-1476.	2.8	161
12	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A $\beta$ 242 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	0.6	140
13	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	4.9	140
14	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
15	Increased Cortical Thickness and Caudate Volume Precede Atrophy in PSEN1 Mutation Carriers. Journal of Alzheimer's Disease, 2010, 22, 909-922.	1.2	136
16	Association of Cerebral Amyloid- $\beta$ 2 Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
17	Prevalence of amyloid- $\beta$ 2 pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	2.8	132
18	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.5	131

#	ARTICLE	IF	CITATIONS
19	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.4	122
20	Plasma miR-34a-5p and miR-545-3p as Early Biomarkers of Alzheimer's Disease: Potential and Limitations. <i>Molecular Neurobiology</i> , 2017, 54, 5550-5562.	1.9	119
21	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	2.5	115
22	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.4	111
23	Cerebrospinal fluid $\beta$ -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 223-230.	2.8	110
24	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- $\beta$ in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
25	Relationship Between $\beta$ -Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 157-167.	1.2	106
26	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	1.7	104
27	CSF sAPP $\beta$ , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.5	100
28	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <i>Journal of Neuroinflammation</i> , 2017, 14, 118.	3.1	99
29	Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. <i>Human Molecular Genetics</i> , 2014, 23, 749-754.	1.4	98
30	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
31	Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome. <i>Alzheimer's and Dementia</i> , 2017, 13, 541-549.	0.4	94
32	Cognitively Preserved Subjects with Transitional Cerebrospinal Fluid $\beta$ -Amyloid 1-42 Values Have Thicker Cortex in Alzheimer's Disease Vulnerable Areas. <i>Biological Psychiatry</i> , 2011, 70, 183-190.	0.7	93
33	Alzheimer's disease associated with Down syndrome: a genetic form of dementia. <i>Lancet Neurology</i> , 2021, 20, 930-942.	4.9	93
34	<i>APOE</i> -by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015, 6, 26663-26674.	0.8	92
35	Synaptic phosphorylated $\beta$ -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017, 140, 3204-3214.	3.7	90
36	A nonsynonymous mutation in <i>PLCG2</i> reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. <i>Acta Neuropathologica</i> , 2019, 138, 237-250.	3.9	87

#	ARTICLE	IF	CITATIONS
37	Correlates of cerebrospinal fluid levels of oligomeric- and total- $\beta$ -synuclein in premotor, motor and dementia stages of Parkinson's disease. <i>Journal of Neurology</i> , 2015, 262, 294-306.	1.8	85
38	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2016, 132, 213-224.	3.9	83
39	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
40	Periodontal disease as a possible cause for Alzheimer's disease. <i>Periodontology 2000</i> , 2020, 83, 242-271.	6.3	76
41	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2018-2023.	1.5	75
42	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. <i>Nature Communications</i> , 2019, 10, 4766.	5.8	73
43	Cerebrospinal Fluid Biomarkers and Memory Present Distinct Associations along the Continuum from Healthy Subjects to AD Patients. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 319-326.	1.2	66
44	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 499-509.	0.4	65
45	Alzheimer's disease in Down syndrome: An overlooked population for prevention trials. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 703-713.	1.8	63
46	COVID-19-associated ophthalmoparesis and hypothalamic involvement. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2020, 7, .	3.1	62
47	Distinct Functional Activity of the Precuneus and Posterior Cingulate Cortex During Encoding in the Preclinical Stage of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 31, 517-526.	1.2	59
48	CSF sAPP $\beta$ , YKL-40, and NfL along the ALS-FTD spectrum. <i>Neurology</i> , 2018, 91, e1619-e1628.	1.5	59
49	Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018, 12, 609.	1.4	59
50	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	13.7	58
51	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
52	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018, 9, 34691-34698.	0.8	57
53	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015, 138, e400-e400.	3.7	56
54	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1725-1733.	1.4	56

#	ARTICLE	IF	CITATIONS
55	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	0.9	55
56	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.5	54
57	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	54
58	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 719-726.	1.2	53
59	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	3.9	53
60	Nanoscale structure of amyloid- $\beta^2$ plaques in Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 5181.	1.6	52
61	Further understanding the connection between Alzheimer's disease and Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1065-1077.	0.4	52
62	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017, 8, 104706-104716.	0.8	51
63	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S87-S98.	1.2	50
64	Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. <i>Journal of Neural Transmission</i> , 2011, 118, 259-262.	1.4	49
65	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	7.1	48
66	Cognitive functions in multiple sclerosis: impact of gray matter integrity. <i>Multiple Sclerosis Journal</i> , 2014, 20, 424-432.	1.4	47
67	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.4	47
68	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	2.8	47
69	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	1.9	45
70	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	3.7	45
71	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the C9orf72 expansion mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 162-168.	0.9	44
72	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	1.8	44

#	ARTICLE	IF	CITATIONS
73	Cerebrospinal Fluid Anti-Amyloid- $\beta$ 2 Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1-7.	1.2	43
74	Epilepsy in Down Syndrome: A Highly Prevalent Comorbidity. <i>Journal of Clinical Medicine</i> , 2021, 10, 2776.	1.0	43
75	Cortical microstructural correlates of astrogliosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.5	42
76	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid- $\beta$ Peptide Aggregation. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 643-657.	1.2	41
77	Altered topology of the functional speech production network in non-fluent/agrammatic variant of PPA. <i>Cortex</i> , 2018, 108, 252-264.	1.1	41
78	The nonlinear relationship between cerebrospinal fluid A $\beta$ 42 and tau in preclinical Alzheimer's disease. <i>PLoS ONE</i> , 2018, 13, e0191240.	1.1	41
79	Atrophy in the Thalamus But Not Cerebellum Is Specific for C9orf72 FTD and ALS Patients: An Atlas-Based Volumetric MRI Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 45.	1.7	40
80	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 710-717.	2.4	39
81	Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 127-134.	1.3	38
82	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 539-546.	1.2	38
83	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 797-819.	1.2	38
84	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	1.2	37
85	Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 93-100.	1.2	35
86	Consensus statement of the International Summit on Intellectual Disability and Dementia related to end-of-life care in advanced dementia. <i>Journal of Applied Research in Intellectual Disabilities</i> , 2017, 30, 1160-1164.	1.3	35
87	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	1.5	34
88	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	1.5	34
89	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.4	34
90	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	1.6	33

#	ARTICLE	IF	CITATIONS
91	Opportunities, barriers, and recommendations in Down syndrome research. <i>Translational Science of Rare Diseases</i> , 2021, 5, 99-129.	1.6	33
92	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
93	Association of Apolipoprotein E $\epsilon$ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
94	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	3.6	32
95	Evolving brain structural changes in PSEN1 mutation carriers. <i>Neurobiology of Aging</i> , 2015, 36, 1261-1270.	1.5	30
96	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. <i>Developmental Neurobiology</i> , 2019, 79, 716-737.	1.5	30
97	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
98	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	4.9	29
99	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 909-918.	1.2	28
100	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	1.6	28
101	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 1-10.	1.2	28
102	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.4	27
103	Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis. <i>PLoS ONE</i> , 2013, 8, e74203.	1.1	26
104	Assessing general cognitive and adaptive abilities in adults with Down syndrome: a systematic review. <i>Journal of Neurodevelopmental Disorders</i> , 2019, 11, 20.	1.5	26
105	Atrophy of Basal Forebrain Initiates with Tau Pathology in Individuals at Risk for Alzheimer's Disease. <i>Cerebral Cortex</i> , 2020, 30, 2083-2098.	1.6	25
106	Diagnosis of prodromal and Alzheimer's disease dementia in adults with Down syndrome using neuropsychological tests. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12047.	1.2	25
107	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	1.2	25
108	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease Families with PSEN1 Mutations. <i>Neurodegenerative Diseases</i> , 2011, 8, 202-207.	0.8	24

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017, 53, 192.e1-192.e4.	1.5	24
110	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	2.7	24
111	Rare Variants in <i>PLD3</i> Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. <i>Human Mutation</i> , 2015, 36, 1226-1235.	1.1	23
112	Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer's Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 671-681.	1.2	23
113	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
114	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	4.4	21
115	Association between cerebrospinal fluid tau and brain atrophy is not related to clinical severity in the Alzheimer's disease continuum. <i>Psychiatry Research - Neuroimaging</i> , 2011, 192, 140-146.	0.9	19
116	Cortical microstructure in the amyotrophic lateral sclerosis "frontotemporal dementia continuum. <i>Neurology</i> , 2020, 95, e2565-e2576.	1.5	19
117	Evolving Brain Functional Abnormalities in PSEN1 Mutation Carriers: A Resting and Visual Encoding fMRI Study. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 165-175.	1.2	19
118	Consensus statement of the international summit on intellectual disability and Dementia related to post-diagnostic support. <i>Aging and Mental Health</i> , 2018, 22, 1406-1415.	1.5	18
119	Annexin A5 prevents amyloid- $\beta$ -induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 9391.	1.6	18
120	The A $\beta$ 1-42/A $\beta$ 1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than A $\beta$ 1-42 alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
121	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
122	The amyloid- $\beta$ isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease. <i>Molecular Medicine Reports</i> , 2012, 5, 1111-1115.	1.1	17
123	White Matter Abnormalities Track Disease Progression in PSEN1 Autosomal Dominant Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 827-835.	1.2	17
124	Elevated YKL-40 and low sAPP $\beta$ :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTL. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	0.9	17
125	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021, 17, 605-617.	0.4	17
126	Distinctive Oculomotor Behaviors in Alzheimer's Disease and Frontotemporal Dementia. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 603790.	1.7	17



#	ARTICLE	IF	CITATIONS
127	Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 16805.	1.6	17
128	Association of cortical microstructure with amyloid- $\beta^2$ and tau: impact on cognitive decline, neurodegeneration, and clinical progression in older adults. <i>Molecular Psychiatry</i> , 2021, 26, 7813-7822.	4.1	17
129	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	3.7	17
130	Patterns of Performance on the Modified Cued Recall Test in Spanish Adults With Down Syndrome With and Without Dementia. <i>American Journal on Intellectual and Developmental Disabilities</i> , 2015, 120, 481-489.	0.8	16
131	Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort. <i>Neurobiology of Aging</i> , 2018, 62, 245.e1-245.e7.	1.5	16
132	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 505-513.	1.2	16
133	Exosome release and cargo in Down syndrome. <i>Developmental Neurobiology</i> , 2019, 79, 639-655.	1.5	15
134	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1489-1496.	1.2	14
135	Early Detection of Learning Difficulties when Confronted with Novel Information in Preclinical Alzheimer's Disease Stage 1. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 855-870.	1.2	14
136	The Behavioral and Psychological Symptoms of Dementia in Down Syndrome Scale (BPSD-DS II): Optimization and Further Validation1. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 1505-1527.	1.2	14
137	Mechanisms Involved in Epileptogenesis in Alzheimer's Disease and Their Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4307.	1.8	14
138	A novel PSEN1 gene mutation (L235R) associated with familial early-onset Alzheimer's disease. <i>Neuroscience Letters</i> , 2011, 496, 40-42.	1.0	13
139	Expansion mutation in C9ORF72 does not influence plasma progranulin levels in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2012, 33, 1851.e17-1851.e19.	1.5	13
140	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 175-180.	1.1	13
141	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	1.7	13
142	Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders. <i>Cell Metabolism</i> , 2022, 34, 269-284.e9.	7.2	13
143	Conducting clinical trials in persons with Down syndrome: summary from the NIH INCLUDE Down syndrome clinical trials readiness working group. <i>Journal of Neurodevelopmental Disorders</i> , 2022, 14, 22.	1.5	13
144	Identifying Earlier Alzheimer's Disease: Insights from the Preclinical and Prodromal Phases. <i>Neurodegenerative Diseases</i> , 2012, 10, 158-160.	0.8	12

#	ARTICLE	IF	CITATIONS
145	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	2.8	12
146	Sleep Disorders in Adults with Down Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 3012.	1.0	12
147	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12062.	1.2	12
148	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PIB-PET images and correlation with CSF concentrations of A $\beta$ 2 species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	1.4	11
149	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021, 17, 1499-1508.	0.4	11
150	Comparison of 2 Diagnostic Criteria for the Behavioral Variant of Frontotemporal Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 469-476.	0.9	10
151	Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 211-225.	1.2	10
152	Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain. <i>Journal of Clinical Medicine</i> , 2021, 10, 3931.	1.0	10
153	Markers of early changes in cognition across cohorts of adults with Down syndrome at risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12184.	1.2	10
154	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	3.0	10
155	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	4.4	9
156	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016, 38, 215.e13-215.e14.	1.5	9
157	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	1.2	9
158	Risk of intracranial haemorrhage and ischaemic stroke after convexity subarachnoid haemorrhage in cerebral amyloid angiopathy: international individual patient data pooled analysis. <i>Journal of Neurology</i> , 2022, 269, 1427-1438.	1.8	9
159	The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease. <i>Journal of Clinical Medicine</i> , 2021, 10, 4582.	1.0	9
160	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 353-356.	0.6	8
161	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 58-67.	1.5	8
162	The Intersection of Intellectual Disability and Dementia: Report of The International Summit on Intellectual Disability and Dementia. <i>Gerontologist</i> , The, 2019, 59, 411-419.	2.3	8

#	ARTICLE	IF	CITATIONS
163	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1327-1333.	1.2	7
164	Quality Care for People with Intellectual Disability and Advanced Dementia: Guidance on Service Provision. <i>Journal of Palliative Medicine</i> , 2018, 21, 1344-1352.	0.6	7
165	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	1.2	7
166	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. <i>Aphasiology</i> , 2021, 35, 240-266.	1.4	7
167	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	2.8	7
168	Accelerated long-term forgetting over three months in asymptomatic APOE $\epsilon$ 4 carriers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 477-484.	1.7	7
169	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	1.4	7
170	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	4.4	7
171	Accelerated long-term forgetting in individuals with subjective cognitive decline and amyloid $\beta$ positivity. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1037-1049.	1.3	6
172	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	3.0	6
173	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. <i>Frontiers in Neurology</i> , 2021, 12, 750543.	1.1	6
174	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	1.2	5
175	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017, 13, 1072-1074.	0.4	5
176	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	1.2	5
177	Atypical astroglial pTDP43 pathology in astroglial predominant tauopathy. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 1109-1113.	1.8	5
178	O5a02a04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2016, 12, P380.	0.4	4
179	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020, 10, 13755.	1.6	4
180	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4

#	ARTICLE	IF	CITATIONS
181	Myelin loss in <i>C9orf72</i> hexanucleotide expansion carriers. <i>Journal of Neuroscience Research</i> , 2022, 100, 1862-1875.	1.3	4
182	P4-320: NEUROPSYCHOLOGICAL ASSESSMENT OF ADULTS WITH DOWN SYNDROME USING THE CAMCOG-DS: A LONGITUDINAL COHORT STUDY. , 2014, 10, P903-P903.		3
183	[O3 <sup>10</sup> ]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.	0.4	3
184	Fatal worsening of late-onset cerebellar ataxia with neuronal intranuclear inclusions due to superimposed meningeal Rosai-Dorfman disease. <i>Movement Disorders</i> , 2008, 23, 1488-1490.	2.2	2
185	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2
186	Effect of <i>REST</i> on brain metabolism in the Alzheimer disease continuum. <i>Annals of Neurology</i> , 2015, 78, 661-662.	2.8	2
187	Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium. <i>Alzheimer's and Dementia</i> , 2022, 18, 1957-1968.	0.4	2
188	Cerebral Amyloid Angiopathy-Related Inflammation in Down Syndrome-Related Alzheimer Disease. <i>Neurology</i> , 2022, , 10.1212/WNL.0000000000200704.	1.5	2
189	DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients. <i>Biomedicines</i> , 2022, 10, 1380.	1.4	2
190	P1 <sup>277</sup> : CORRELATION BETWEEN INNOTEST <sup>®</sup> AND THE FULLY AUTOMATED LUMIPULSE <sup>®</sup> G PLATFORM FOR THE ANALYSIS OF $\beta$ -AMYLOID $1\text{--}42$ AND TOTAL TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P388.	0.4	1
191	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	1
192	Feasibility and Long-Term Compliance to Continuous Positive Airway Pressure Treatment in Adults With Down Syndrome, a Genetic Form of Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2022, 16, 838412.	1.4	1
193	Calsyntenin1 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
194	P3-230: CSF $\beta$ -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
195	IC-P-217: CSF $\beta$ -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
196	P1-046: ROLE OF PLD3 RARE VARIANTS IN EUROPEAN SPORADIC ALZHEIMER'S DISEASE PATIENTS. , 2014, 10, P319-P320.		0
197	P1-121: Comparison of different $\beta$ -amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia. , 2015, 11, P387-P387.		0
198	La enfermedad de Alzheimer: El próximo desafío para las personas con síndrome de Down. <i>Revista Médica Internacional Sobre El Síndrome De Down</i> , 2015, 19, 35.	0.1	0

#	ARTICLE	IF	CITATIONS
199	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
200	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
201	La prevención de las demencias, un reto inmediato. Revista Clinica Espanola, 2016, 216, 483-484.	0.2	0
202	[P1â€“366]: WEIGHT LOSS MIGHT BE A NONâ€“COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.4	0
203	[P3â€“274]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. Alzheimer's and Dementia, 2017, 13, P1048.	0.4	0
204	[P1â€“238]: THE SAPP1 <sup>2</sup> /YKLâ€“40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P335.	0.4	0
205	[P2â€“259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR ADâ€“RELATED SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P712.	0.4	0
206	P4â€“076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P1463.	0.4	0
207	P2â€“262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.4	0
208	O5â€“04â€“01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.4	0
209	P1â€“293: IDENTIFICATION OF EXOSOMAL MICRORNAs AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.4	0
210	P2â€“230: CHALLENGES ASSOCIATED WITH BIOMARKERâ€“BASED CLASSIFICATIONS SYSTEMS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P756.	0.4	0
211	ICâ€“Pâ€“148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P119.	0.4	0
212	O2â€“09â€“01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P558.	0.4	0
213	AmyQ: An index to accurately measure cerebral amyloid load. Alzheimer's and Dementia, 2020, 16, e039735.	0.4	0
214	Oligodendroglial alterations in FTD caused by C9orf72 expansion. Alzheimer's and Dementia, 2020, 16, e040196.	0.4	0
215	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. Alzheimer's and Dementia, 2020, 16, e041255.	0.4	0
216	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. Alzheimer's and Dementia, 2020, 16, e041500.	0.4	0

#	ARTICLE	IF	CITATIONS
217	The relationship between cortical microstructural changes and in vivo amyloid $\beta$ and tau in aging and preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e041626.	0.4	0
218	Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDP $\beta$ 43 aberrant inclusions. <i>Alzheimer's and Dementia</i> , 2020, 16, e042953.	0.4	0
219	1 H $\beta$ MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.4	0
220	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020, 16, e043491.	0.4	0
221	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044772.	0.4	0
222	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045268.	0.4	0
223	Biomarkers and trial-ready cohorts for Alzheimer's disease clinical trials in the Down syndrome population. <i>Alzheimer's and Dementia</i> , 2020, 16, e046943.	0.4	0
224	Blood-based detection of early-stage Alzheimer using multiomics and machine learning. <i>Alzheimer's and Dementia</i> , 2020, 16, e047334.	0.4	0
225	Fluid biomarkers for Alzheimer's disease in Down syndrome: Current status and novel trends. , 2022, , 97-128.		0
226	A Nonsynonymous Mutation in PLCG2 Reduces the Risk of Alzheimer's Disease, Dementia with Lewy-Bodies and Frontotemporal Dementia, and Increases the Likelihood of Longevity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
227	The crucial history of Down syndrome. <i>Lancet Neurology</i> , The, 2022, 21, 222.	4.9	0
228	Late-onset epileptic seizures in adults with Down syndrome are linked to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
229	Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
230	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
231	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
232	Neuropsychological correlates of plasma NfL in adults with Down syndrome. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
233	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and population-based study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
234	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
235	Transcriptome-wide characterization of the frontal cortex in FTL D.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e049569.	0.4	0